UNSPSC 51111629: Clofarabine

This classification denotes a ribonucleotide reductase inhibitor and purine antagonist with the molecular formula C10H11ClFN5O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 762RDY0Y2H, chemically known as 9h-purin-6-amine, 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)- but generally known as clofarabine, which bears US NIH Compound Identifier 119182. European Medicines Agency schedules Clofarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21902.

UNSPSC 51111629 Clofarabine is a Commodity code covering procurement of this purine nucleoside antimetabolite chemotherapy drug, used primarily in treatment of pediatric acute lymphoblastic leukemia and certain other hematologic malignancies. State and local governments procure clofarabine through established pharmaceutical supply chains, typically via hospital systems, integrated health networks, state Medicaid programs, and correctional health services that maintain oncology or specialized chemotherapy inventories. The drug is sourced as a manufactured pharmaceutical product subject to FDA approval and pricing regulation, with procurement tied to clinical demand, insurance formulary status, and bulk purchasing agreements negotiated at the state or regional health authority level.

The source material contains no recent state or local contract opportunities tagged to this code. Without documented solicitations, addenda, or RFP/RFQ/IFB/ITB notice activity in the dataset, no geographic spread, issuing-body concentration, or representative recent awards can be characterized. Clofarabine procurement by public health systems typically occurs through standing pharmaceutical vendor relationships, group purchasing organization (GPO) agreements, or state centralized purchasing rather than competitive solicitations with published response dates — a pattern common to commoditized prescription drugs where pricing and supply are managed through negotiated frameworks rather than project-specific RFQs.